139 related articles for article (PubMed ID: 21273493)
1. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Vaughn DE
Diabetes Care; 2011 Mar; 34(3):666-8. PubMed ID: 21273493
[TBL] [Abstract][Full Text] [Related]
2. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
[TBL] [Abstract][Full Text] [Related]
4. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.
Pettis RJ; Hirsch L; Kapitza C; Nosek L; Hövelmann U; Kurth HJ; Sutter DE; Harvey NG; Heinemann L
Diabetes Technol Ther; 2011 Apr; 13(4):443-50. PubMed ID: 21355716
[TBL] [Abstract][Full Text] [Related]
5. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations.
Muchmore DB; Vaughn DE
J Diabetes Sci Technol; 2010 Mar; 4(2):419-28. PubMed ID: 20307403
[TBL] [Abstract][Full Text] [Related]
6. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.
Vaughn DE; Yocum RC; Muchmore DB; Sugarman BJ; Vick AM; Bilinsky IP; Frost GI
Diabetes Technol Ther; 2009 Jun; 11(6):345-52. PubMed ID: 19459762
[TBL] [Abstract][Full Text] [Related]
7. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
[TBL] [Abstract][Full Text] [Related]
8. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.
Morrow L; Muchmore DB; Ludington EA; Vaughn DE; Hompesch M
Diabetes Technol Ther; 2011 Oct; 13(10):1039-45. PubMed ID: 21714645
[TBL] [Abstract][Full Text] [Related]
9. Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.
Heinemann L; Hompesch M; Flacke F; Simms P; Pohl R; Albus K; Pfützner A; Steiner S
J Diabetes Sci Technol; 2011 May; 5(3):681-6. PubMed ID: 21722583
[TBL] [Abstract][Full Text] [Related]
10. Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus.
Gentile S; Guarino G; Strollo F; Romano M; Genovese S; Masarone M; Ceriello A
Diabetes Res Clin Pract; 2016 Mar; 113():179-86. PubMed ID: 26803356
[TBL] [Abstract][Full Text] [Related]
11. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
Andersen G; Meiffren G; Lamers D; DeVries JH; Ranson A; Seroussi C; Alluis B; Gaudier M; Soula O; Heise T
Diabetes Obes Metab; 2018 Nov; 20(11):2627-2632. PubMed ID: 29923294
[TBL] [Abstract][Full Text] [Related]
12. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.
Malone JK; Woodworth JR; Arora V; Yang H; Campaigne BN; Hallé JP; Yale JF; Grossman LD
Clin Ther; 2000 Feb; 22(2):222-30. PubMed ID: 10743981
[TBL] [Abstract][Full Text] [Related]
13. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase.
Muchmore DB; Vaughn DE
J Diabetes Sci Technol; 2012 Jul; 6(4):764-72. PubMed ID: 22920800
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes.
Danne T; Becker RH; Heise T; Bittner C; Frick AD; Rave K
Diabetes Care; 2005 Sep; 28(9):2100-5. PubMed ID: 16123473
[TBL] [Abstract][Full Text] [Related]
15. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
Ahmed AB; Home PD
Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
[TBL] [Abstract][Full Text] [Related]
16. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
17. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
18. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
[TBL] [Abstract][Full Text] [Related]
19. Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study.
Kazda C; Leohr J; Liu R; Reddy S; Dellva MA; Loh MT; Hardy T; Plum-Mörschel L
Diabetes Obes Metab; 2022 Feb; 24(2):196-203. PubMed ID: 34595812
[TBL] [Abstract][Full Text] [Related]
20. Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.
Leohr J; Kazda C; Liu R; Reddy S; Dellva MA; Matzopoulos M; Loh MT; Hardy T; Klein O; Kapitza C
Diabetes Obes Metab; 2022 Feb; 24(2):187-195. PubMed ID: 34605142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
